Last reviewed · How we verify

Azilsartan Medoxomil and amlodipine — Competitive Intelligence Brief

Azilsartan Medoxomil and amlodipine (Azilsartan Medoxomil and amlodipine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + calcium channel blocker combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker + calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Azilsartan Medoxomil and amlodipine (Azilsartan Medoxomil and amlodipine) — Takeda. Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Azilsartan Medoxomil and amlodipine TARGET Azilsartan Medoxomil and amlodipine Takeda phase 3 Angiotensin II receptor blocker + calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
Telmisartan + Amlodipine Telmisartan + Amlodipine Daewon Pharmaceutical Co., Ltd. marketed Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
Losartan (+) amlodipine Losartan (+) amlodipine Organon and Co marketed Angiotensin II receptor blocker + calcium channel blocker combination AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Fimasartan and Amlodipine Fimasartan and Amlodipine Boryung Pharmaceutical Co., Ltd phase 3 Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (fimasartan); L-type calcium channel (amlodipine)
Valsartan + Amlodipine besilate Valsartan + Amlodipine besilate Novartis phase 3 Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
AZM X mg + AML Y mg AZM X mg + AML Y mg Celltrion phase 3 Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (azilsartan); L-type calcium channel (amlodipine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + calcium channel blocker combination class)

  1. Organon and Co · 1 drug in this class
  2. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azilsartan Medoxomil and amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/azilsartan-medoxomil-and-amlodipine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: